An alternative to lifelong antiretroviral therapy (ART) is needed to achieve durable control of HIV-1. Here, we show that adeno-associated virus (AAV) delivery of two rhesus macaque antibodies to the simian immunodeficiency virus (SIV) envelope glycoprotein (Env) with potent neutralization and antibody-dependent cellular cytotoxicity can prevent viral rebound in macaques infected with barcoded SIV239M after discontinuing suppressive ART. After AAV administration, sustained antibody expression with minimal antidrug antibody responses was achieved in all but one animal. After ART withdrawal, SIV replication rebounded within 2 weeks in all control animals but remained <15 copies per milliliter in plasma for more than a year in four of the eight animals that received AAV vectors encoding Env-specific antibodies. Viral sequences from animals that rebounded with delayed kinetics exhibited restricted clonal diversity and antibody escape mutations in Env. Thus, sustained expression of antibodies with potent antiviral activity can afford durable, ART-free containment of pathogenic SIV infection.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1126/sciimmunol.adq4973 | DOI Listing |
Ann Intern Med
March 2025
Massachusetts General Hospital, Boston, Massachusetts; Mbarara University of Science and Technology, Mbarara, Uganda; and Kabwohe Clinical Research Center, Kabwohe, Sheema, Uganda (S.A.).
Background: Data on the prevalence of coronary atherosclerotic disease (CAD) in the African region among people with and without HIV are lacking.
Objective: To estimate the prevalence of CAD in Uganda and determine whether well-controlled HIV infection is associated with increased presence or severity of CAD.
Design: Cross-sectional study.
J Immunol
February 2025
Gritstone Bio, Inc, Emeryville, CA, United States.
While therapeutic vaccines are a promising strategy for inducing human immunodeficiency virus (HIV) control, HIV vaccines tested to date have offered limited benefit to people living with HIV. The barriers to success may include the use of vaccine platforms and/or immunogens that drive weak or suboptimal immune responses, immune escape and/or immune dysfunction associated with chronic infection despite effective antiretroviral therapy. Combining vaccines with immune modulators in a safe manner may address some of the challenges and thus increase the efficacy of therapeutic HIV vaccines.
View Article and Find Full Text PDFMed Trop Sante Int
December 2024
Service de médecine interne, CHU de Libreville, BP 2228, Libreville, Gabon.
Background: HIV/AIDS infection is endemic in sub-Saharan Africa. It is manifested by a variety of opportunistic diseases that usually occur when the CD4 count is below 200/mm, but also during the immune restoration syndrome (IRS) that occurs under highly active antiretroviral therapy (HAART). Autoimmune and inflammatory diseases are rarely associated with this condition.
View Article and Find Full Text PDFFront Immunol
March 2025
Department of Neurology, Yale University School of Medicine, New Haven, CT, United States.
Background: Trafficking of immune cells to the central nervous system is hypothesized to facilitate HIV entry and immune-induced neuronal injury and is mediated by surface proteins such as chemokine receptors and α4 integrin. We longitudinally assessed immune cell activation and surface marker expression in cerebrospinal fluid (CSF) and blood and their relationship with CSF HIV RNA beginning during primary HIV infection (PHI) before and after antiretroviral therapy (ART).
Methods: Longitudinal paired blood and CSF were obtained in ART-naïve PHI (<12 month since infection) participants; some independently initiated ART during follow up.
Front Immunol
March 2025
Beijing Key Laboratory for HIV/AIDS Research, Clinical and Research Center for Infectious Diseases, Beijing Youan Hospital, Capital Medical University, Beijing, China.
Elite controllers (ECs) and post-treatment controllers (PTCs) represent important models for achieving a functional cure for HIV. This review synthesizes findings from immunological, genetic, and virological studies to compare the mechanisms underlying HIV suppression in ECs and PTCs. Although ECs maintain viral control without antiretroviral therapy (ART), PTCs achieve suppression following ART discontinuation.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!